Tonix Pharmaceuticals (NASDAQ:TNXP) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXPGet Free Report) in a research report issued on Wednesday. The brokerage set a “sell” rating on the stock.

Separately, Dawson James initiated coverage on Tonix Pharmaceuticals in a research note on Wednesday, February 28th. They set a “buy” rating and a $3.00 target price for the company.

Get Our Latest Analysis on Tonix Pharmaceuticals

Tonix Pharmaceuticals Stock Performance

NASDAQ:TNXP opened at $0.19 on Wednesday. Tonix Pharmaceuticals has a 1 year low of $0.17 and a 1 year high of $3.80. The stock has a market cap of $5.10 million, a price-to-earnings ratio of -0.02 and a beta of 2.21. The business has a fifty day moving average of $0.33 and a 200-day moving average of $0.44.

Tonix Pharmaceuticals (NASDAQ:TNXPGet Free Report) last announced its earnings results on Monday, April 1st. The company reported ($0.86) earnings per share for the quarter. The company had revenue of $3.78 million during the quarter, compared to analyst estimates of $3.95 million. On average, equities research analysts predict that Tonix Pharmaceuticals will post -8.58 EPS for the current year.

Institutional Investors Weigh In On Tonix Pharmaceuticals

Several hedge funds have recently modified their holdings of the stock. Armistice Capital LLC lifted its holdings in shares of Tonix Pharmaceuticals by 160.0% during the fourth quarter. Armistice Capital LLC now owns 3,770,000 shares of the company’s stock valued at $1,519,000 after purchasing an additional 2,320,000 shares during the last quarter. Sabby Management LLC purchased a new stake in shares of Tonix Pharmaceuticals during the third quarter valued at $680,000. JPMorgan Chase & Co. lifted its holdings in shares of Tonix Pharmaceuticals by 490.1% during the first quarter. JPMorgan Chase & Co. now owns 293,036 shares of the company’s stock valued at $173,000 after purchasing an additional 243,380 shares during the last quarter. State Street Corp lifted its holdings in shares of Tonix Pharmaceuticals by 309.5% during the first quarter. State Street Corp now owns 195,028 shares of the company’s stock valued at $115,000 after purchasing an additional 147,401 shares during the last quarter. Finally, Geode Capital Management LLC lifted its holdings in shares of Tonix Pharmaceuticals by 43.5% during the first quarter. Geode Capital Management LLC now owns 533,511 shares of the company’s stock valued at $315,000 after purchasing an additional 161,659 shares during the last quarter. 82.26% of the stock is owned by hedge funds and other institutional investors.

Tonix Pharmaceuticals Company Profile

(Get Free Report)

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.

Featured Stories

Receive News & Ratings for Tonix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.